Skip to main content

FDA recall, , Moderate risk

Pro Numb Tattoo Numbing Spray

Pro Numb Tattoo Numbing Spray is recalling its Pro Numb Tattoo Numbing Spray because of cGMP deviations.

What happened

Pro Numb Tattoo Numbing Spray LLC, of Palm Bay, Florida, began recalling its Pro Numb Tattoo Numbing Spray on February 2, 2026, because of cGMP deviations. The recall covers the 5% Lidocaine and 4% Lidocaine versions, distributed nationwide in the USA. The FDA added the recall to its Enforcement Report on February 9, 2026, and it was in the weekly enforcement report on February 18, 2026.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is your bottle affected?

2 products

Match the lot code and NDC listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Pro Numb Tattoo Numbing Spray, 5% Lidocaine, [1 fl oz/28.4 ml or 4 oz/120 mL] per bottle

    NDC
    • 83389-111-11
    Lot code
    • J01
    • J14
    • J55
    • J69
  2. Pro Numb Tattoo Numbing Spray, For Sensitive Skin, 4% Lidocaine, [1FL oz/28.4 ml or 4 oz/120 mL] per bottle

    NDC
    • 83389-112-11
    Lot code
    • J15

Recall details

Company began the recall
Sold in

Nationwide in the USA

Company
Pro Numb Tattoo Numbing Spray LLCPalm Bay, Florida
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
98361
Recall numbers
D-0302-2026 to D-0303-2026

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. In FDA's weekly enforcement report

  4. Listed on Recall Canary

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 16, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)